Glytec Receives Five Additional Patent Allowances for its Diabetes Therapy Management Software

Physica System Trabecular Titanium Tibial Plate – 1st Surgery Performed by Dr. Ivan De Martino

Luigi Ferrari, LimaCorporate CEO, commented: "TT Tibial plate is an important addition to the Physica system and will enable LimaCorporate to approach a new segment of the total knee market. 

Virtual Short Course Offers New Insights for Corrosion Prevention and Sustainability of Biomedical Implants and Devices

AMPP’s Corrosion Technical Series is now offering a new 6-hour short course on corrosion prevention in metallic biomaterials and biomedical devices.

Dr. Michael Cantor Named Intuition Robotics 1st Chief Medical Officer

The company recently announced its plan to extend to healthcare.

Patent Image

Glytec,  software solution for personalized diabetes therapy management, announces five new patent allowances for its eGlycemic Management System® (eGMS®), increasing the company’s portfolio to a total of 11 allowed or issued patents, with more than 50 pending.

Three of the new allowances were issued by the United States Patent and Trademark Office and two by the Israel Patent Office. The patents apply to proprietary systems and methods for intravenous and subcutaneous insulin therapies. They also address eGMS® integration with connected device systems — such as those which host and/or store blood glucose data — as well as enterprise health information systems, including electronic medical record systems (EMR); laboratory information systems (LIS); and admission, discharge and transfer systems (ADT).

“Technology innovation is one of Glytec’s core competencies, and it’s a significant investment for the company,” says Glytec’s Senior Vice President Research and Development, Robby Booth. “Our intellectual property protections, both here in the U.S. and abroad, speak to the unique and highly differentiated characteristics of our eGlycemic Management System®. Though, the improved clinical outcomes our clients achieve, and the associated cost savings, are the true testament of its worth.”

Glytec’s President and CEO, Bob Leonard adds: “A recent case study published by one of our clients — a large regional academic medical center — shows annualized savings in excess of $9.7 million using eGMS® to achieve best practice and reduce incidence of hypoglycemia for hospitalized patients. In other studies, we’ve demonstrated how using eGMS® leads to a decrease in readmissions of 35-68% and a sustained drop in A1C levels of 2.6 percentage points for chronic care populations, both of which result in improved quality of care and great economic benefit, especially in light of alternative reimbursement models. eGMS® is an enabling solution of value to health systems, payers and patients alike.”

Statistics from myriad organizations, including American Diabetes Association, International Diabetes Federation, and World Health Organization, point to the fact that diabetes is a global epidemic. “The difficulties associated with diabetes therapy management, especially insulin dosing and titration, are universal,” says Leonard. “Our intensive pursuit of both domestic and international patents formidably positions Glytec for broad geographic growth.”

Past News

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles